LUNAR™ Nanoparticles A Versatile RNA Delivery System Priya Karmali, Arcturus.mp4

The presentation identifies a potent combination of three UNA (Unlocked Nucleomonomer Agent) oligomers that targets all HBV transcripts and covers all known HBV sequences – the most comprehensive HBV genotype coverage reported for a single drug product to date. The combination demonstrated excellent efficacy in mouse models of HBV infection using Lipid-enabled and Unlocked Nucleomonomer Agent RNA (LUNAR™), a novel biodegradable nanoparticle delivery technology with a favorable safety profile.

"Arcturus is delighted to present HBV preclinical data, developed in collaboration with Janssen, at the AASLD Liver meeting 2016," said Joseph E. Payne, Arcturus' President & Chief Executive Officer. "Based on the potent reduction of Hepatitis B surface antigen, and the observed safety profile, LUNAR-HBV has the potential to be part of a new generation of HBV therapies."

Source: https://www.prnewswire.com/new....s-releases/arcturus-